Attorneys General, including Nebraska Attorney General Doug Peterson, have reached a $71 million settlement with Amgen Inc. to resolve allegations that Amgen unlawfully promoted biologic medications Aranesp and Enbrel.
The Attorneys General alleged that Amgen violated state consumer protection laws for promoting dosing frequencies of Aranesp longer than approved by the FDA, promoting Aranesp for anemia without FDA approval, and promoting Enbrel for mild plaque psoriasis though the FDA has approved its use only for chronic moderate to severe plaque psoriasis.
The Attorney General’s office reports Aranesp is used to treat certain types of anemia by stimulating bone marrow to produce red blood cells. Enbrel is used to treat a number of conditions, including plaque psoriasis.
The agreement requires Amgen to reform its marketing and promotional practices.
The other states participating in the settlement are Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming.